Growth failure (GF) is one of the major complications affecting children with inflammatory bowel disease. The faltering is temporary in 40–50% of cases and prolonged in 10–20% in Crohn’s disease (CD). Such failure is rare in children with ulcerative colitis (5%). This complication is often associated with retarded bone development and delayed onset of sexual maturation. The delayed linear growth has a variety of causes including insufficient intake due to anorexia and the inflammatory process with increased energy and protein expenditure. Other factors are increased intestinal loss, secondary hypopituitarism and treatment with steroids. Therapeutic strategies of CD in children have changed this last decade by introducing new therapeutic agents such as topic steroids, immunosuppressors, anti-TNF (antibody and notably in children enteral nutrition which has shown its efficacy in inducing remissions of active CD, restoring nutritional status and stimulation of linear growth. The results of a recent prospective multicentric study over 2 years in 82 CD show that severe GF (–2 SD) is initially present in 15% (n = 12), among them 11 remain < –2SD after 2 years of follow-up. Six patients who were on the normal range initially increased their GF during the follow-up (< –2SD) (total 21% < –2SD (n = 17) at 2 years). At inclusion in this group there was no difference in growth velocity, used of steroids, enteral nutrition or severity of CD as compared to the group with no GF. It suggests that new treatment strategy should be developed in the future for this specific complication of paediatric CD.

1.
Castille RG, Telander RL, Cooney DR, et al: Crohn’s disease in children: Assessment of the progression of disease. Paediatrics 1970;45:386–393.
2.
Kanof ME, Lake AM, Bayless TM: Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 1988;95:1523–1527.
3.
Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO: Growth failure in children with inflammatory bowel disease: A prospective study. Gastroenterology 1993;105:681–691.
4.
Puntis J, McNeish AS, Allan RN: Long-term prognosis of Crohn’s disease with onset in childhood and adolescence. Gut 1984;25:239–236.
5.
Markowitz J, Grancher K, Rosa J, Aiges H, Daum F: Growth failure in paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;16:373–380.
6.
Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM: Growth and clinical course of children with Crohn’s disease. Gut 1993;34:939–943.
7.
Thornton JR, Emmett PM, Heaton KW: Diet and Crohn’s disease: Characteristics of the pre-illness diet. Br Med J 1979;ii:762–764.
8.
Thomas AG, Taylor F, Miller V: Dietary intake and nutritional treatment in childhood Crohn’s disease. J Pediatr Gastroenterol Nutr 1983;17:75–81.
9.
Beeken W: Absorptive defects in young people with regional enteritis. Paediatrics 1973;52:69–74.
10.
Schoelmerich J, Becher MS, Hoppe-Seyler P, Matern S, Haeussinger D, Loehle E: Zinc and vitamin A deficiency in patients with Crohn’s disease is correlated with activity but not with localization or extent of the disease. Hepatogastroenterology 1985;32:34–38.
11.
Kirschner BS, DeFavaro MV, Jensen W: Lactose malabsorption in children and adolescents with inflammatory bowel disease. Gastroenterology 1981;81:829–832.
12.
Kushner RF, Schoeller DA: Resting and total energy expenditure in patients with inflammatory bowel disease. Am J Clin Nutr 1976;29:1073–1088.
13.
Spady DW, Payne PR, Picou D, Waterlow JC: Energy balance during recovery for malnutrition. Am J Clin Nutr 1976;29:1073–1088.
14.
Motil KJ, Grand RJ, Maletskos CJ, Young VR: The effect of disease, drug and diet on whole-body protein metabolism in adolescents with Crohn’s disease and growth failure. J Pediatr 1982;101:345–351.
15.
Varille V, Bellaiche M, De Lagausie P, et al: Resting energy expenditure before and after surgical resection of gut lesions in paediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 1996;23:13–19.
16.
Murch SH: Inflammatory mediators and suppression of growth in paediatric chronic IBD; in Tytgat GNS, Bartelsman JF, Van Deventer SJH (eds): Inflammatory Bowel Disease. Lancaster, Kluwer Academic, 1995, vol 71, pp 598–603.
17.
Skerry TM: The effects of the inflammatory response on bone growth. Eur J Clin Nutr 1994;48:S190–S198.
18.
Issenman RM; Atkinson SA, Radoja C, Fraher L: Longitudinal assessment of growth, mineral metabolism, and bone mass in paediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 1993;17:401–406.
19.
Thomas AG, Miller V, Taylor F, Maycock P, Scrimcoeur CM, Rennie MJ: Whole-body protein turnover in childhood Crohn’s disease. Gut 1992;33:675–677.
20.
Farthing MJ, Campbell CA, Walker-Smith JA, Edwards CR, Rees LH, Dawson AM: Nocturnal growth hormone and gonadotrophin secretion in growth-retarded children with Crohn’s disease. Gut 1981;22:933–938.
21.
Kirschner BS, Sutton MM: Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology 1986;91:830–836.
22.
Thomas AGN, Holly JMP, Taylor F, Miller V: Insulin-like growth factor-1, inulin-like growth factor binding protein-I, and insulin in childhood Crohn’s disease. Gut 1993;34:944–947.
23.
Allen DB, Mullen M, Mullen B: Clinical aspects of allergic disease. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J. Allergy Clin Immunol 1994;93:967–976.
24.
O’Keefe SJD, Ogden J, Rund J, Potter P: Steroids and bowel rest versus elemental diet in the treatment of patients with Crohn’s disease: The effects on protein metabolism and immune function. J Parent Enter Nutr 1989;13:455–460.
25.
Cezard JP, Touati G, Hugot JP, et al: Nutritional treatment in paediatric inflammatory bowel disease; in Tytgat GNJ, Bartelsman JG, Van Deventer SJH: Inflammatory Bowel Disease. Lancaster, Kluwer Academic, 1995, pp 619–625.
26.
Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR: Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology 1995;108:1056–1067.
27.
Seidman E, Giffiths A, Jones A, Issenman R: Semi-elemental diet vs. prednisone in paediatric Crohn’s disease. Gastroenterology 1993;104:A778.
28.
Sanderson IR, Udeen S, Davies PSW, Savage MO, Walker-Smith JA: Remission induced by an elemental diet in small bowel Crohn’s disease. Arch Dis Child 1087;61:123–127.
29.
Belli DC, Siedman E, Bouthillier L, et al: Chronic intermittent elemental diet improves growth failure in children with Crohn’s disease. Gastroenterology 1988;94:603–610.
30.
Aiges H, Markowitz J, Rosa J, Daum F: Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn’s disease. Gastroenterology 1989;97:905–910.
31.
Cezard JP, Messing B: Enteral nutrition in inflammatory bowel diseases: Is there a specific role for elemental diets. Clin Nutr 1993;1:875–881.
32.
Cezard JP, Bellaiche M, Faure C, Bingen E, Navarro J: Role of artificial support in child Crohn’s disease evolution. Gastroenterology 1993;104:A679.
33.
Heuschkel RB, Menache CC, Megerian JT, Baird AE: Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr 2000;31:8–15.
34.
Akobeng AK, Miller V, Stanton J, Elbadri AM, Thomas AG: Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn’s disease. J Pediatr Gastroenterol Nutr 2000;30:78–84.
35.
Fell JME, Paintin M, Arnaud-Battandier F, Beatties RM, Hollis A, Kitching P, Donnet-Hughes A, MacDonald TT, Walker-Smith JA: Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther 2000;14:281–289.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.